Pathogenic bacterial proteins and their anti-inflammatory effects in the eukaryotic host

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 3, 2009, Pages 214-227

  Sun, Jun ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acetylation; Anti inflammation; AvrA; Bacteria; Bacterial tail specific protease; Effector; Inflammation; Intestine; Phosphorylation; Salmonella; Type three secretion system; Ubiquitination

Indexed keywords

ANTIINFLAMMATORY AGENT; BACTERIAL PROTEIN; BACTERIAL VACCINE; CHEMOTAXIS INHIBITORY PROTEIN; CHLAMYDIAL PROTEASOME LIKE ACTIVITY FACTOR; EXTRACELLULAR ADHERENCE PROTEIN; FILAMENTOUS HEMAGGLUTININ; MICROORGANISM PROTEIN; PROTEIN AVRA; PROTEIN CHLADUB1; PROTEIN CHLADUB2; PROTEIN CIF; PROTEIN CT441; PROTEIN OSPF; SALMONELLA SECRETED FACTOR L; TAIL SPECIFIC PROTEASE; UNCLASSIFIED DRUG; YERSINIA OUTER PROTEIN H; YERSINIA OUTER PROTEIN J;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BORDETELLA BRONCHISEPTICA; CHLAMYDIA; ENZYME ACTIVITY; ESCHERICHIA COLI; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SALMONELLA; SHIGELLA; SIGNAL TRANSDUCTION; TYPE III SECRETION SYSTEM; YERSINIA;

EID: 73549101321     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789151986     Document Type: Review

References (102)

1. Weiss, U. Inflammation. Nature, 2008, 454(7203), 427.
2. Prat, C.; Bestebroer, J.; de Haas, C. J.; van Strijp, J. A.; van Kessel, K. P. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol., 2006, 177(11), 8017-8026.
3. Chavakis, T.; Hussain, M.; Kanse, S. M.; Peters, G.; Bretzel, R. G.; Flock, J. I.; Herrmann, M.; Preissner, K. T. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med., 2002, 8(7), 687-693.
4. Peschel, A. How do bacteria resist human antimicrobial peptides? Trends Microbiol., 2002, 10(4), 179-186.
5. Ye, Z.; Petrof, E. O.; Boone, D.; Claud, E. C.; Sun, J. Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination. Am. J. Pathol., 2007, 171(3), 882-892.
6. Collier-Hyams, L. S.; Zeng, H.; Sun, J.; Tomlinson, A. D.; Bao, Z. Q.; Chen, H.; Madara, J. L.; Orth, K.; Neish, A. S. Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-kappa B pathway. J. Immunol., 2002, 169(6), 2846-2850.
7. Lad, S. P.; Li, J.; da Silva Correia, J.; Pan, Q.; Gadwal, S.; Ulevitch, R. J.; Li, E. Cleavage of p65/RelA of the NF-kappaB pathway by Chlamydia. Proc. Natl. Acad. Sci. USA, 2007, 104(8), 2933-2938.
8. Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454 (7203), 428-435.
9. Mattoo, S.; Lee, Y. M.; Dixon, J. E. Interactions of bacterial effector proteins with host proteins. Curr. Opin. Immunol., 2007, 19(4), 392-401.
10. Schlumberger, M. C.; Hardt, W. D. Salmonella type III secretion effectors: pulling the host cell's strings. Curr. Opin. Microbiol., 2006, 9(1), 46-54.
11. Patel, J. C.; Rossanese, O. W.; Galan, J. E. The functional interface between Salmonella and its host cell: opportunities for therapeutic intervention. Trends Pharmacol. Sci., 2005, 26(11), 564-570.
12. Patel, J. C.; Hueffer, K.; Lam, T. T.; Galan, J. E. Diversification of a Salmonella virulence protein function by ubiquitin-dependent differential localization. Cell, 2009, 137(2), 283-294.
13. Galan, J. E. Salmonella interactions with host cells: type III secretion at work. Annu. Rev. Cell. Dev. Biol., 2001, 17, 53-86.
14. Mota, L. J.; Cornelis, G. R. The bacterial injection kit: type III secretion systems. Ann. Med., 2005, 37(4), 234-249.
15. Coburn, B.; Sekirov, I.; Finlay, B. B. Type III secretion systems and disease. Clin. Microbiol. Rev., 2007, 20(4), 535-549.
16. Coburn, B.; Li, Y.; Owen, D.; Vallance, B. A.; Finlay, B. B. Salmonella enterica serovar Typhimurium pathogenicity island 2 is necessary for complete virulence in a mouse model of infectious enterocolitis. Infect. Immun., 2005, 73(6), 3219-3227.
17. Staskawicz, B. J.; Mudgett, M. B.; Dangl, J. L.; Galan, J. E. Common and contrasting themes of plant and animal diseases. Science, 2001, 292(5525), 2285-9.
18. Lara-Tejero, M.; Galan, J. E. Salmonella enterica serovar typhimurium pathogenicity island 1-encoded type III secretion system translocases mediate intimate attachment to nonphagocytic cells. Infect. Immun., 2009, 77(7), 2635-2642.
19. Galan, J. E. SnapShot: effector proteins of type III secretion systems. Cell, 2007, 130(1), 192.
20. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med., 1998, 339(8), 520-532.
21. Lad, S. P.; Yang, G.; Scott, D. A.; Wang, G.; Nair, P.; Mathison, J.; Reddy, V. S.; Li, E. Chlamydial CT441 is a PDZ domain-containing tail-specific protease that interferes with the NF-kappaB pathway of immune response. J. Bacteriol., 2007, 189(18), 6619-6625.
22. Stephens, R. S.; Kalman, S.; Lammel, C.; Fan, J.; Marathe, R.; Aravind, L.; Mitchell, W.; Olinger, L.; Tatusov, R. L.; Zhao, Q.; Koonin, E. V.; Davis, R. W. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science, 1998, 282(5389), 754-759.
23. Zhong, G.; Fan, P.; Ji, H.; Dong, F.; Huang, Y. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J. Exp. Med., 2001, 193(8), 935-942.
24. Kubori, T.; Galan, J. E. Salmonella type III secretion-associated protein InvE controls translocation of effector proteins into host cells. J. Bacteriol., 2002, 184(17), 4699-4708.
25. Garner, M. J.; Hayward, R. D.; Koronakis, V. The Salmonella pathogenicity island 1 secretion system directs cellular cholesterol redistribution during mammalian cell entry and intracellular trafficking. Cell. Microbiol., 2002, 4(3), 153-165.
26. Galan, J. E.; Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines. Nature, 2006, 444(7119), 567-573.
27. Salcedo, S. P.; Holden, D. W. Bacterial interactions with the eukaryotic secretory pathway. Curr. Opin. Microbiol., 2005, 8(1), 92-98.
28. Hardt, W. D.; Galan, J. E. A secreted Salmonella protein with homology to an avirulence determinant of plant pathogenic bacteria. Proc. Natl. Acad. Sci. USA, 1997, 94(18), 9887-9892.
29. Ben-Barak, Z.; Streckel, W.; Yaron, S.; Cohen, S.; Prager, R.; Tschape, H. The expression of the virulence-associated effector protein gene avrA is dependent on a Salmonella enterica-specific regulatory function. Int. J. Med. Microbiol., 2006, 296(1), 25-38.
30. Streckel, W.; Wolff, A. C.; Prager, R.; Tietze, E.; Tschape, H. Expression profiles of effector proteins SopB, SopD1, SopE1, and AvrA differ with systemic, enteric, and epidemic strains of Salmonella enterica. Mol. Nutr. Food Res., 2004, 48(7), 496-503.
31. Jones, R. M.; Wu, H.; Wentworth, C.; Luo, L.; Collier-Hyams, L.; Neish, A. S. Salmonella AvrA Coordinates Suppression of Host Immune and Apoptotic Defenses via JNK Pathway Blockade. Cell. Host Microbe, 2008, 3(4), 233-244.
32. Perkins, N. D. Integrating cell-signalling pathways with NFkappaB and IKK function. Nat. Rev. Mol. Cell. Biol., 2007, 8(1), 49-62.
33. Gilmore, T. D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene, 2006, 25(51), 6680-6684.
34. Brasier, A. R. The NF-kappaB regulatory network. Cardiovasc. Toxicol., 2006, 6(2), 111-130.
35. Gilmore, T. D.; Herscovitch, M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene, 2006, 25(51), 6887-6899.
36. Bonizzi, G.; Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol., 2004, 25(6), 280-288.
37. Deng, J.; Miller, S. A.; Wang, H. Y.; Xia, W.; Wen, Y.; Zhou, B. P.; Li, Y.; Lin, S. Y.; Hung, M. C. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell., 2002, 2(4), 323-334.
38. Deng, J.; Xia, W.; Miller, S. A.; Wen, Y.; Wang, H. Y.; Hung, M. C. Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol. Carcinog., 2004, 39(3), 139-146.
39. Sun, J.; Hobert, M. E.; Duan, Y.; Rao, A. S.; He, T. C.; Chang, E. B.; Madara, J. L. Crosstalk between NF-kappaB and beta-catenin pathways in bacterial-colonized intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2005, 289(1), G129-37.
40. Morin, P. J. beta-catenin signaling and cancer. Bioessays, 1999, 21(12), 1021-1030.
41. Roux, P. P.; Blenis, J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev., 2004, 68(2), 320-344.
42. Weston, C. R.; Davis, R. J. The JNK signal transduction pathway. Curr. Opin. Cell Biol., 2007, 19(2), 142-149.
43. Boone, D. L.; Turer, E. E.; Lee, E. G.; Ahmad, R. C.; Wheeler, M. T.; Tsui, C.; Hurley, P.; Chien, M.; Chai, S.; Hitotsumatsu, O.; McNally, E.; Pickart, C.; Ma, A. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Iimmunol., 2004, 5(10), 1052-1060.
44. Hitotsumatsu, O.; Ahmad, R. C.; Tavares, R.; Wang, M.; Philpott, D.; Turer, E. E.; Lee, B. L.; Shiffin, N.; Advincula, R.; Malynn, B. A.; Werts, C.; Ma, A. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity, 2008, 28(3), 381-390.
45. Wertz, I. E.; O'Rourke, K. M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D. L.; Ma, A.; Koonin, E. V.; Dixit, V. M. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature, 2004, 430(7000), 694-699.
46. Sun, J.; Hobert, M. E.; Rao, A. S.; Neish, A. S.; Madara, J. L. Bacterial activation of beta-catenin signaling in human epithelia. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287(1), G220-7.
47. Duan, Y.; Liao, A. P.; Kuppireddi, S.; Ye, Z.; Ciancio, M. J.; Sun, J. beta-Catenin activity negatively regulates bacteria-induced inflammation. Lab. Invest., 2007, 87(6), 613-624.
48. Boyle, E. C.; Brown, N. F.; Finlay, B. B. Salmonella enterica serovar Typhimurium effectors SopB, SopE, SopE2 and SipA disrupt tight junction structure and function. Cell Microbiol., 2006, 8(12), 1946-1957.
49. Liao, A. P.; Petrof, E. O.; Kuppireddi, S.; Zhao, Y.; Xia, Y.; Claud, E. C.; Sun, J. Salmonella type III effector AvrA stabilizes cell tight junctions to inhibit inflammation in intestinal epithelial cells. PLoS ONE, 2008, 3(6), e2369.
50. Le Negrate, G.; Faustin, B.; Welsh, K.; Loeffler, M.; Krajewska, M.; Hasegawa, P.; Mukherjee, S.; Orth, K.; Krajewski, S.; Godzik, A.; Guiney, D. G.; Reed, J. C. Salmonella secreted factor L deubiquitinase of Salmonella typhimurium inhibits NF-kappaB, suppresses IkappaBalpha ubiquitination and modulates innate immune responses. J. Immunol., 2008, 180(7), 5045-5056.
51. Orth, K. Function of the Yersinia effector YopJ. Curr. Opin. Microbiol., 2002, 5(1), 38-43.
52. Orth, K.; Xu, Z.; Mudgett, M. B.; Bao, Z. Q.; Palmer, L. E.; Bliska, J. B.; Mangel, W. F.; Staskawicz, B.; Dixon, J. E. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science, 2000, 290(5496), 1594-1597.
53. Zhang, Y.; Ting, A. T.; Marcu, K. B.; Bliska, J. B. Inhibition of MAPK and NF-kappa B pathways is necessary for rapid apoptosis in macrophages infected with Yersinia. J. Immunol., 2005, 174(12), 7939-7949.
54. Mukherjee, S.; Keitany, G.; Li, Y.; Wang, Y.; Ball, H. L.; Goldsmith, E. J.; Orth, K. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science, 2006, 312(5777), 1211-1214.
55. Mukherjee, S.; Hao, Y. H.; Orth, K. A newly discovered post-translational modification - the acetylation of serine and threonine residues. Trends Biochem. Sci., 2007, 32(5), 210-216.
56. Mittal, R.; Peak-Chew, S. Y.; McMahon, H. T. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc. Natl. Acad. Sci. USA, 2006, 103(49), 18574-18579.
57. Zhou, H.; Monack, D. M.; Kayagaki, N.; Wertz, I.; Yin, J.; Wolf, B.; Dixit, V. M. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J. Exp. Med., 2005, 202(10), 1327-1332.
58. Sweet, C. R.; Conlon, J.; Golenbock, D. T.; Goguen, J.; Silverman, N. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell Microbiol., 2007, 9(11), 2700-2715.
59. Bhoj, V. G.; Chen, Z. J. Ubiquitylation in innate and adaptive immunity. Nature, 2009, 458(7237), 430-437.
60. Trompouki, E.; Hatzivassiliou, E.; Tsichritzis, T.; Farmer, H.; Ashworth, A.; Mosialos, G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature, 2003, 424(6950), 793-796.
61. Sauvonnet, N.; Lambermont, I.; van der Bruggen, P.; Cornelis, G. R. YopH prevents monocyte chemoattractant protein 1 expression in macrophages and T-cell proliferation through inactivation of the phosphatidylinositol 3-kinase pathway. Mol. Microbiol., 2002, 45(3), 805-815.
62. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 1995, 378(6559), 785-789.
63. Vanhaesebroeck, B.; Alessi, D. R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J., 2000, 346 Pt 3, 561-576.
64. Gerke, C.; Falkow, S.; Chien, Y. H. The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation. J. Exp. Med., 2005, 201(3), 361-371.
65. Ranganathan, R.; Ross, E. M. PDZ domain proteins: scaffolds for signaling complexes. Curr. Biol., 1997, 7(12), R770-3.
66. Misaghi, S.; Balsara, Z. R.; Catic, A.; Spooner, E.; Ploegh, H. L.; Starnbach, M. N. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol. Microbiol., 2006, 61(1), 142-150.
67. Le Negrate, G.; Krieg, A.; Faustin, B.; Loeffler, M.; Godzik, A.; Krajewski, S.; Reed, J. C. ChlaDub1 of Chlamydia trachomatis suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol., 2008, 10(9), 1879-1892.
68. Dong, F.; Pirbhai, M.; Zhong, Y.; Zhong, G. Cleavage-dependent activation of a chlamydia-secreted protease. Mol. Microbiol., 2004, 52(5), 1487-1494.
69. Arbibe, L.; Kim, D. W.; Batsche, E.; Pedron, T.; Mateescu, B.; Muchardt, C.; Parsot, C.; Sansonetti, P. J. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat. Immunol., 2007, 8(1), 47-56.
70. Li, H.; Xu, H.; Zhou, Y.; Zhang, J.; Long, C.; Li, S.; Chen, S.; Zhou, J. M.; Shao, F. The phosphothreonine lyase activity of a bacterial type III effector family. Science, 2007, 315(5814), 1000-1003.
71. Yuk, M. H.; Harvill, E. T.; Cotter, P. A.; Miller, J. F. Modulation of host immune responses, induction of apoptosis and inhibition of NF-kappaB activation by the Bordetella type III secretion system. Mol. Microbiol., 2000, 35(5), 991-1004.
72. Abramson, T.; Kedem, H.; Relman, D. A. Modulation of the NF-kappaB pathway by Bordetella pertussis filamentous hemagglutinin. PLoS ONE, 2008, 3(11), e3825.
73. Marches, O.; Ledger, T. N.; Boury, M.; Ohara, M.; Tu, X.; Goffaux, F.; Mainil, J.; Rosenshine, I.; Sugai, M.; De Rycke, J.; Oswald, E. Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol. Microbiol., 2003, 50(5), 1553-1567.
74. Samba-Louaka, A.; Nougayrede, J. P.; Watrin, C.; Jubelin, G.; Oswald, E.; Taieb, F. Bacterial cyclomodulin Cif blocks the host cell cycle by stabilizing the cyclin-dependent kinase inhibitors p21 and p27. Cell Microbiol., 2008, 10(12), 2496-2508.
75. Nougayrede, J. P.; Boury, M.; Tasca, C.; Marches, O.; Milon, A.; Oswald, E.; De Rycke, J. Type III secretion-dependent cell cycle block caused in HeLa cells by enteropathogenic Escherichia coli O103. Infect. Iimmun., 2001, 69(11), 6785-6795.
76. Jubelin, G.; Chavez, C. V.; Taieb, F.; Banfield, M. J.; Samba-Louaka, A.; Nobe, R.; Nougayrede, J. P.; Zumbihl, R.; Givaudan, A.; Escoubas, J. M.; Oswald, E. Cycle inhibiting factors (CIFs) are a growing family of functional cyclomodulins present in invertebrate and mammal bacterial pathogens. PLoS ONE, 2009, 4(3), e4855.
77. Nougayrede, J. P.; Taieb, F.; De Rycke, J.; Oswald, E., Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol., 2005, 13(3), 103-110.
78. Haggar, A.; Shannon, O.; Norrby-Teglund, A.; Flock, J. I. Dual effects of extracellular adherence protein from Staphylococcus aureus on peripheral blood mononuclear cells. J. Infect. Dis., 2005, 192(2), 210-217.
79. Scriba, T. J.; Sierro, S.; Brown, E. L.; Phillips, R. E.; Sewell, A. K.; Massey, R. C. The Staphyloccous aureus Eap protein activates expression of proinflammatory cytokines. Infect. Immun., 2008, 76(5), 2164-2168.
80. Duesbery, N. S.; Webb, C. P.; Leppla, S. H.; Gordon, V. M.; Klimpel, K. R.; Copeland, T. D.; Ahn, N. G.; Oskarsson, M. K.; Fukasawa, K.; Paull, K. D.; Vande Woude, G. F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science, 1998, 280(5364), 734-737.
81. Zhu, Y.; Li, H.; Long, C.; Hu, L.; Xu, H.; Liu, L.; Chen, S.; Wang, D. C.; Shao, F. Structural insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. Mol. Cell., 2007, 28(5), 899-913.
82. Hsu, Y.; Jubelin, G.; Taieb, F.; Nougayrede, J. P.; Oswald, E.; Stebbins, C. E. Structure of the cyclomodulin Cif from pathogenic Escherichia coli. J. Mol. Biol., 2008, 384(2), 465-477.
83. Charpentier, X.; Oswald, E. Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J. Bacteriol., 2004, 186(16), 5486-5495.
84. Holm, L.; Sander, C. Dali: a network tool for protein structure comparison. Trends Biochem. Sci., 1995, 20(11), 478-480.
85. Yao, Q.; Cui, J.; Zhu, Y.; Wang, G.; Hu, L.; Long, C.; Cao, R.; Liu, X.; Huang, N.; Chen, S.; Liu, L.; Shao, F. A bacterial type III effector family uses the papain-like hydrolytic activity to arrest the host cell cycle. Proc. Natl. Acad. Sci. USA, 2009, 106(10), 3716-3721.
86. Crow, A.; Race, P. R.; Jubelin, G.; Varela Chavez, C.; Escoubas, J. M.; Oswald, E.; Banfield, M. J. Crystal structures of Cif from bacterial pathogens Photorhabdus luminescens and Burkholderia pseudomallei. PLoS ONE, 2009, 4(5), e5582.
87. Hao, Y. H.; Wang, Y.; Burdette, D.; Mukherjee, S.; Keitany, G.; Goldsmith, E.; Orth, K. Structural requirements for Yersinia YopJ inhibition of MAP kinase pathways. PLoS ONE, 2008, 3(1), e1375.
88. Chen, D.; Chai, J.; Hart, P. J.; Zhong, G. Identifying catalytic residues in CPAF, a Chlamydia-secreted protease. Arch. Biochem. Biophys., 2009, 485(1), 16-23.
89. Huang, Z.; Feng, Y.; Chen, D.; Wu, X.; Huang, S.; Wang, X.; Xiao, X.; Li, W.; Huang, N.; Gu, L.; Zhong, G.; Chai, J. Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. Cell Host Microbe, 2008, 4(6), 529-542.
90. Chavakis, T.; Wiechmann, K.; Preissner, K. T.; Herrmann, M. Staphylococcus aureus interactions with the endothelium: the role of bacterial "secretable expanded repertoire adhesive molecules" (SERAM) in disturbing host defense systems. Thromb. Haemost., 2005, 94(2), 278-285.
91. Chavakis, T.; Preissner, K. T.; Herrmann, M. The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol., 2007, 28(9), 408-418.
92. t Hart, B. A.; Amor, S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Curr. Opin. Neurol., 2003, 16(3), 375-383.
93. Xie, C.; Alcaide, P.; Geisbrecht, B. V.; Schneider, D.; Herrmann, M.; Preissner, K. T.; Luscinskas, F. W.; Chavakis, T. Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J. Exp. Med., 2006, 203(4), 985-994.
94. Su, S. B.; Gong, W.; Gao, J. L.; Shen, W.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. A seven-transmembrane, G proteincoupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med., 1999, 189(2), 395-402.
95. Le, Y.; Gong, W.; Tiffany, H. L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N. M.; Gao, J. L.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci., 2001, 21(2), RC123.
96. Le, Y.; Yazawa, H.; Gong, W.; Yu, Z.; Ferrans, V. J.; Murphy, P. M.; Wang, J. M., The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J. Immunol., 2001, 166(3), 1448-14451.
97. Cui, Y.; Le, Y.; Yazawa, H.; Gong, W.; Wang, J. M. Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease. J. Leukoc. Biol., 2002, 72(4), 628-635.
98. Sartor, R. B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract., 2006, 3(7), 390-407.
99. Sartor, R. B.; Muehlbauer, M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr. Gastroenterol. Reports, 2007, 9(6), 497-507.
100. Marceau, M.; Dubuquoy, L.; Caucheteux-Rousseaux, C.; Foligne, B.; Desreumaux, P.; Simonet, M. Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acidinduced colitis in the mouse. Infect. Immun., 2004, 72(4), 2438-2441.
101. Zauberman, A.; Tidhar, A.; Levy, Y.; Bar-Haim, E.; Halperin, G.; Flashner, Y.; Cohen, S.; Shafferman, A.; Mamroud, E. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS ONE, 2009, 4(6), e5938.
102. Finlay, B. B.; McFadden, G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell, 2006, 124(4), 767-782.